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Abstract 
Objective— Atherosclerosis is a vascular disease that involves lesion 
formation at sites of disturbed flow under the influence of genetic and 
environmental factors. Endothelial expression of adhesion molecules that 
enable infiltration of immune cells is important for lesion development. 
Platelet/endothelial cell adhesion molecule-1 (PECAM-1; CD31) is an adhesion 
and signaling receptor expressed by many cells involved in atherosclerotic 
lesion development. PECAM-1 transduces signals required for 
proinflammatory adhesion molecule expression at atherosusceptible sites; 
thus, it is predicted to be proatherosclerotic. PECAM-1 also inhibits 
inflammatory responses, on which basis it is predicted to be atheroprotective. 
Methods and Results— We evaluated herein the effect of PECAM-1 
deficiency on development of atherosclerosis in LDL receptor–deficient mice. 
We found that PECAM-1 has both proatherosclerotic and atheroprotective 
effects, but that the former dominate in the inner curvature of the aortic arch 
whereas the latter dominate in the aortic sinus, branching arteries, and 
descending aorta. Endothelial cell expression of PECAM-1 was sufficient for its 
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atheroprotective effects in the aortic sinus but not in the descending aorta, 
where the atheroprotective effects of PECAM-1 also required its expression on 
bone marrow–derived cells. 
Conclusion— We conclude that PECAM-1 influences initiation and progression 
of atherosclerosis both positively and negatively, and that it does so in a site-
specific manner. 
 
Keywords: PECAM-1, CD31, atherosclerosis, LDL-receptor, inflammation 
Atherosclerosis is a chronic inflammatory disease that involves 
formation, at discrete regions within the vasculature, of lesions 
characterized by the presence of inflammatory cells, lipid deposits, and 
extracellular matrix deposition.1 Atherosclerotic lesions form 
preferentially at sites of vessel branching or high vessel curvature, 
which are exposed to low shear stresses or oscillatory or turbulent 
flow; however, genetic and environmental factors that determine 
circulating lipid levels, gender and immune status strongly influence 
lesion development in atherosusceptible regions.2 Endothelial cells 
respond to low shear stress in atherosusceptible regions with increased 
expression of adhesion molecules that enable recruitment and 
infiltration of immune cells that contribute to lesion development.3 
Nevertheless, the roles of individual adhesion molecules in regulating 
atherosclerotic lesion development are not completely understood. 
PECAM-1 is expressed on the surfaces of many cells involved in 
atherosclerotic lesion development, including monocytes, lymphocytes, 
platelets, and endothelial cells.4 PECAM-1 expression is equally 
distributed over the entire surface of the aorta, including advanced 
lesions, and does not appear to be affected by hemodynamic forces or 
lipid levels.5,6 PECAM-1 engages in homophilic7 and heterophilic8 
interactions at sites of cell–cell contact. On the basis of its role as a 
critical component of a mechanotransducing complex that is required 
for expression of proinflammatory adhesion molecules at 
atherosusceptible sites,9 PECAM-1 has been predicted to have 
proatherosclerotic properties.3 However, PECAM-1 also functions to 
inhibit both systemic and organ-specific inflammatory responses10–18 
and the oxidative environment in the vasculature,19,20 on the basis of 
which PECAM-1 might be predicted to be atheroprotective. 
The purpose of this study was to determine whether the 
proatherosclerotic or atheroprotective effects of PECAM-1 dominate in 
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an in vivo situation. We therefore evaluated the effect of PECAM-1 
deficiency on development of atherosclerosis in LDL receptor–deficient 
mice. We found that PECAM-1 has both proatherosclerotic and 
atheroprotective effects in LDLR-deficient mice, but that the former 
dominate in the inner curvature of the aortic arch whereas the latter 
dominate in the aortic sinus, branching arteries, and descending aorta. 
On the basis of these findings, we conclude that PECAM-1 influences 
initiation and progression of atherosclerosis both positively and 
negatively, and that it does so in a site-specific manner. 
Methods 
Animals and Diet 
Mice were maintained in a facility free of well defined pathogens 
under the supervision of the Biological Resource Center at the Medical 
College of Wisconsin (MCW). Animal protocols were approved by the 
MCW Institutional Animal Care and Use Committee. Mice were housed 
in groups of 4 per cage, maintained under alternating 12-hour light 
and dark cycles, and had free access to food and water. PECAM-1–
deficient (pecam-1−/−) mice,21 backcrossed for more than 10 
generations onto a C57BL/6J background, were crossbred with LDL 
receptor–deficient (ldlr−/−) mice (Jackson Laboratory, Bar Harbor, 
Maine). Subsequently, pecam-1+/−ldlr−/− offspring were bred to obtain 
pecam-1+/+ldlr−/− and pecam-1−/−ldlr−/− mice. The resulting genetic 
background was 98.6% C57BL/6 and 1.4% 129Sv. Six- to 8-week-old 
male and female pecam-1+/+ldlr−/− and pecam-1−/− ldlr−/− were placed 
on a high-fat diet (HFD; Western-Type Diet TD 88137; Harlan Teklad) 
containing 42% of calories derived from fat. Age- and gender-matched 
pecam-1+/+ldlr−/− relative to pecam-1−/− ldlr−/− mice gained similar 
amounts of weight over 24 weeks on the HFD (Table).  
Table. Plasma Lipid Analysis and Weight Gain of Mice After 24 Weeks on the 
HFD 
Variable Pecam-
1+/+ldlr−/− 
Male 
Pecam-
1−/−ldlr−/− 
Male 
Pecam-
1+/+ldlr−/− 
Female 
Pecam-
1−/−ldlr−/− 
Female 
Results are expressed as mean±SE. No statistically significant differences were found 
between the groups. 
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Variable Pecam-
1+/+ldlr−/− 
Male 
Pecam-
1−/−ldlr−/− 
Male 
Pecam-
1+/+ldlr−/− 
Female 
Pecam-
1−/−ldlr−/− 
Female 
Cholesterol, 
mg/dL 
1335±280 
(n=6) 
1605±167 
(n=8) 
1048±120 
(n=9) 
1291±152 (n=9) 
Triglycerides, 
mg/dL 
302±97 (n=5) 354±62 (n=8) 120±25 (n=9) 184±19 (n=9) 
HDL 
Cholesterol, 
mg/dL 
335±36 (n=7) 374±29 (n=7) 340±25 (n=9) 367±16 (n=9) 
Body Weight, g 37±2.8 (n=10) 44±3.8 (n=8) 33±1.6 (n=14) 34±1.7 (n=11) 
Plasma Lipid Analyses 
Plasma aliquots (100 μL) of blood collected by cardiac puncture 
from anesthetized mice were stored at −80°C. Levels of total 
cholesterol, HDL cholesterol, and triglycerides, which were determined 
in individual aliquots by the clinical laboratory at Children’s Hospital of 
Wisconsin using the Vitros 5.1 fractional shortening (FS) Chemistry 
System (Ortho-Clinical Diagnostics), did not differ significantly 
between age- and gender-matched pecam-1+/+ldlr−/− and pecam-
1−/−ldlr−/− mice after 24 weeks on the HFD (Table 1). 
Preparation of Mouse Aortas and Quantification of 
Atherosclerosis 
The heart and aorta of each animal were perfused, dissected 
out, and subjected to quantification of atherosclerosis as previously 
described.22,23 Briefly, to quantitate atherosclerosis in the aortic sinus, 
the heart was embedded in optimal cutting temperature (OCT) 
medium and frozen, after which serial sections (10 μm) were taken 
from the aortic sinus and valve region.22 Images were obtained of the 
sections after staining with oil red O (neutral lipid; counterstaining 
with hematoxylin), and lesion area was quantified using SPOT image 
analysis software (Diagnostic Instruments). The percent lesion area in 
each section was calculated as follows: lesion area/total area 
surrounded by aortic wall × 100. The mean percent atherosclerotic 
lesion area for each animal was determined by averaging 4 to 6 
sections from each mouse, using 60 to 80 μm intervals between 
sections. To quantify atherosclerosis in the aorta by the en face 
method, the entire aortic tree was dissected free of fat and other 
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tissue. The aorta was stained with oil red O and digitally scanned. 
Lesion area was assessed using Adobe Photoshop software and 
expressed as a percent of the total surface area encompassed by the 
aortic arch, inner curvature of the arch, thoracic aorta, abdominal 
aorta, or total aorta as indicated. 
Immunohistochemistry 
Serial cryostat sections of aortic sinus adjacent to oil red O–
stained sections were stained with Sirius Red to detect collagen or 
antimouse CD68 (1:100, AbD Serotec) and a tyramide amplification 
plus kit (Perkin Elmer) to identify macrophages. Sections stained with 
anti-CD68 were counterstained with DAPI to visualize nuclei. 
Quantification of macrophage and collagen content was determined by 
computer-assisted image analysis and expressed as percentage of 
lesion area. 
Ex Vivo Micro-CT Imaging and Quantification of Plaque 
Volume 
Mouse aortic specimens were dissected free of fat and incubated 
overnight with 2% osmium tetroxide (OT).24,25 Prepared aortic samples 
were placed in a 1.5-mL plastic microcentrifuge tube and subjected to 
computed tomography (CT) scanning using a custom Keck microfocal 
X-ray imaging system at the Zablocki VA Medical Center (Milwaukee, 
Wisc). Details of the microfocal x-ray CT system and CT reconstruction 
methods were described previously.26 Briefly, the imaging system 
comprises a 3-μm focal-spot cone-beam X-ray source, precise 
specimen manipulation stage, and image intensifier coupled to a 
charge-coupled device (CCD) camera. Planar images (360, in 1o 
increments) of the aortic samples were acquired with source-to-
specimen distance of 4.6 cm, source-to-detector distance of 71.5 cm, 
source current of 222 μA, and source voltage of 36 kV. A Feldkamp 
algorithm was used to produce isotropic (4973 pixels) 3-D 
reconstructions with 12.8 μm/pixel resolution. Floating-point grayscale 
voxel values were scaled to 8-bit [0(air)-255(punctate accumulations 
of OT)] for normalization and reduction of memory and processing 
requirements. Data were visualized and morphometrics (based on 
regional lesion volume) performed using multidimensional imaging 
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software Analyze 8.0.26,27 A single observer defined threshold-based 
images of the vessel wall (threshold 52) and plaque (threshold 93). 
Lesion volumes were quantified in defined areas of the aortic arch 
(24.1±2.5 mm2) and proximal parts of the three major branching 
arteries, including the innominate (13.1±0.5 mm2), left common 
carotid (4.8±0.2 mm2), and left subclavian (3.6±0.2 mm2) arteries. 
Creation of Radiation Chimeras 
Bone marrow cells were collected from the femur and tibia of 
pecam-1+/+ldlr−/− or pecam-1−/−ldlr−/− donor mice and the small 
mononuclear cell-enriched fraction was injected into irradiated, 4- to 
6-week-old pecam-1+/+ldlr−/− or pecam-1−/−ldlr−/− recipient mice as 
previously described.13 Transplant recipients were fed a normal chow 
diet for 4 weeks, after which they were maintained on the HFD for an 
additional 24 weeks. Flow cytometry was performed on whole blood 
obtained from recipients at 12 weeks after transplantation to ensure 
that full engraftment had taken place, with both CD3-positive 
leukocytes and platelets examined for PECAM-1 expression 
(supplemental Figure I). 
Statistical Analysis 
Data are presented for each individual animal or as mean±SEM. 
Differences between means were analyzed using 2-tailed unpaired 
Student t test or 2-way ANOVA followed by Bonferroni posthoc testing 
using GraphPad Prism 4 software (GraphPad Software Inc). 
Results 
PECAM-1 Deficiency Renders LDLR-Deficient Mice More 
Susceptible to Development of Atherosclerotic Lesions 
in the Aortic Sinus 
To determine whether the mechanosensory or antiinflammatory 
role of PECAM-1 dominates in atherosclerosis, we tested the effect of 
PECAM-1 deficiency on development and progression of atherosclerosis 
in LDL receptor–deficient mice.28 We first evaluated the time course 
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over which atherosclerotic lesions develop in the aortic sinus (Figure 
1A and 1B). Both pecam-1−/−ldlr−/− and pecam-1+/+ldlr−/− mice 
developed similarly small atherosclerotic lesions in the aortic sinus 
after 8 weeks on the HFD (fractional lesion areas [FLA] −4.6±0.7% 
[n=7] and 3.7±0.5% [n=8], respectively). However, after 16 weeks 
on the HFD, atherosclerotic lesions in the aortic sinuses of pecam-
1−/−ldlr−/− mice were significantly larger than were those in pecam-
1+/+ldlr−/− mice (FLA −36.4±2.0% [n=8] and 25.9±1.7% [n=8], 
respectively) and this difference persisted through 24 weeks on the 
HFD (FLA −41.8±1.2% [n=14] and 36.3±1.6% [n=20], respectively). 
Differences in aortic sinus lesion areas between pecam-1−/−ldlr−/− and 
pecam-1+/+ldlr−/− mice were statistically significant when both genders 
were evaluated together and when each gender was evaluated 
separately (data not shown). Because the composition of 
atherosclerotic lesions, along with lesion size, is critically important in 
atherogenesis, cell and matrix components of the lesions were also 
characterized by analyzing macrophage and collagen content, 
respectively. After 24 weeks on the HFD, macrophage content in 
atherosclerotic lesions of the aortic sinus was significantly greater in 
pecam-1−/−ldlr−/− mice than in pecam-1+/+ldlr−/− mice (Figure 1C and 
1D), whereas collagen deposition was similar between the 2 groups of 
mice (Figure 1E and 1F). These results indicate that PECAM-1 inhibits 
development of, and macrophage accumulation in, atherosclerotic 
lesions in the aortic sinus of LDLR-deficient mice.  
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Figure 1. PECAM-1 suppresses atherosclerotic lesion development in the aortic 
sinuses of LDLR-deficient mice. A, Each symbol represents the mean percent 
atherosclerotic lesion area calculated from 4 to 6 oil red O–stained sections spanning 
the aortic sinus of an individual pecam-1+/+ldlr−/− (filled squares) or pecam-1−/−ldlr−/− 
(open circles) mouse maintained on a HFD for the indicated time. Horizontal lines 
indicate mean percent lesion area for each group of animals. Asterisks denote 
statistically significant differences between groups (**P<0.01, ***P<0.001). B, 
Representative oil red O–stained aortic sinus sections from pecam-1+/+ldlr−/− (top) and 
pecam-1−/−ldlr−/− (bottom) mice fed a HFD for 24 weeks. C, Quantitative analysis of 
macrophage content in aortic sinus lesions of pecam-1+/+ldlr−/− (filled bars) or pecam-
1−/−ldlr−/− (open bars) mice fed a HFD for 24 weeks. Results are expressed as the 
mean percent of atherosclerotic lesion area occupied by CD68+ macrophages ±SE. 
Asterisks denote statistically significant differences between groups (**P<0.01). D, 
Representative anti-CD68–stained aortic sinus sections from pecam-1+/+ldlr−/− (top) 
and pecam-1−/−ldlr−/− (bottom) mice. E, Quantitative analysis of collagen deposition in 
aortic sinus lesions of pecam-1+/+ldlr−/− (filled bars) or pecam-1−/−ldlr−/− Figure 1 
(Continued). (open bars) mice fed a HFD for 24 weeks. Results are expressed as the 
mean percent of atherosclerotic lesion area containing collagen, as identified by 
staining with Sirius Red, ±SE. F, Representative Sirius Red–stained aortic sinus 
sections from pecam-1+/+ldlr−/− (top) and pecam-1−/−ldlr−/− (bottom) mice. 
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PECAM-1 Deficiency Renders LDLR-Deficient Mice More 
Susceptible to Development of Atherosclerotic Lesions 
in the Descending Aorta 
We next assessed the effect of PECAM-1 deficiency on 
development of atherosclerotic lesions in the aorta of LDLR-deficient 
mice by en face staining with oil red O. We found that lesion area in 
the aortic arch as a whole did not differ significantly between pecam-
1+/+ldlr−/− and pecam-1−/−ldlr−/− mice after 24 weeks on the HFD 
(Figure 2). However, lesion areas in both the thoracic and abdominal 
aorta, and thus the total aorta, were significantly greater in pecam-
1−/−ldlr−/− relative to pecam-1+/+ldlr−/− mice (Figure 2). These results 
reveal that, as it does in the aortic sinus, PECAM-1 inhibits 
development of atherosclerotic lesions in the descending aorta of 
LDLR-deficient mice.  
 
Figure 2. PECAM-1 suppresses atherosclerosis in the descending aorta. A, Each 
symbol represents the percent of total area of the indicated section of aorta that 
stained positively for oil red O in individual pecam-1+/+ldlr−/− (filled squares) or 
pecam-1−/− ldlr−/− (open circles) mice maintained on a HFD for 24 weeks. Horizontal 
lines indicate mean percent lesion area in the indicated aortic section, including the 
aortic arch, thoracic aorta, abdominal aorta, and total aorta (aortic arch+thoracic 
aorta+ abdominal aorta), for each group of animals. Asterisks denote statistically 
significant differences between groups (***P<0.001). B, Representative oil red O–
stained aortas from pecam-1+/+ldlr−/− (top) and pecam-1−/−ldlr−/− (bottom) mice 
maintained on a HFD for 24 weeks. 
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PECAM-1 Affects Atherosclerotic Lesion Development in 
the Aortic Arch in a Site-Specific Manner 
We observed a distinct pattern of plaque development in aortic 
arches of pecam-1+/+ldlr−/− relative to pecam-1−/− ldlr−/− mice by en 
face staining with oil red O. The pecam-1+/+ldlr−/− mice had 
significantly larger lesions along the inner curvature of the arch but 
smaller lesions in branching arteries compared to the pecam-1−/−ldlr−/− 
mice (Figure 3A and 3B). We therefore decided to evaluate the effect 
of PECAM-1 deficiency on development of atherosclerotic lesions in the 
aortic arch in more detail using another method. We used 
microcomputed tomography (micro-CT), which is a powerful imaging 
technique for visualization of small specimens.24 Micro-CT has been 
recently used to visualize the artery wall and early atherosclerotic 
lesions both with25 and without29 OT as a contrast agent. Micro-CT 
images revealed striking differences in plaque localization in pecam-
1+/+ ldlr−/− relative to pecam-1−/−ldlr−/−mice. Specifically, in pecam-
1+/+ldlr−/− mice, lesions were less extensive in the aortic branches and 
more extensive along the inner curvature of the aortic arch (Figure 
3C). In contrast, pecam-1−/−ldlr−/− mice developed substantial 
atherosclerosis in branching arteries but few lesions along the inner 
curvature of the arch (Figure 3). By visualizing the specimen in 3 
dimensions, it is apparent that plaque was extensively distributed 
along the inner curvature of the arch and only minimally present along 
the lateral wall of the innominate artery (IA) and left common carotid 
artery (LCCA) of pecam-1+/+ldlr−/− mice (supplemental Figure II), 
whereas plaque was broadly distributed along the lateral walls of all 3 
branching arteries and restricted to small patches along the inner 
curvature of the arch in pecam-1−/−ldlr−/− mice (supplemental Figure 
III). We also used OT in micro-CT to quantify plaque volume over 
defined areas of vessel wall within discrete regions of the aortic arch. 
We found that pecam-1+/+ldlr−/− mice had significantly more plaque 
volume than did pecam-1−/−ldlr−/− mice along the inner curvature of 
the arch; however, this was offset by the presence of significantly 
greater plaque volume in the branching arteries of pecam-1−/−ldlr−/− 
relative to pecam-1+/+ldlr−/− mice, such that plaque burden in the total 
aortic arch as a whole was similar in pecam-1+/+ldlr−/− and pecam-
1−/−ldlr−/− mice (Figure 3D). Overall, these results indicate that 
PECAM-1 expression in LDLR-deficient mice is proatherosclerotic along 
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the inner curvature of the aortic arch but atheroprotective in aortic 
branches.  
 
Figure 3. PECAM-1 influences the site of atherosclerotic lesion development in the 
aortic arch. A, Each symbol represents the percent of inner curvature area of the 
aortic arch that stained positively for oil red O in individual pecam-1+/+ldlr−/− (filled 
squares) or pecam-1−/−ldlr−/− (open circles) mice maintained on a HFD for 24 weeks. 
Horizontal lines indicate mean percent lesion area for each group of animals. Asterisks 
denote statistically significant differences between groups (***P<0.001). B, 
Representative oil red O–stained aortas from pecam-1+/+ldlr−/− (left) and pecam-
1−/−ldlr−/− (right) mice maintained on a HFD for 24 weeks. C, Representative false-
color micro-CT images of osmium tetroxide-stained aortas from pecam-1+/+ldlr−/− 
(left) and pecam-1−/−ldlr−/− (right) mice maintained on a HFD for 24 weeks. Lesions 
along the inner curvature (IC) of the aortic arch are shown in green, lesions in the 3 
major branches emanating from the aortic arch (innominate artery [IA], left common 
carotid artery [LCCA], and left subclavian artery [LSCA]) are shown in magenta, and 
lesions in the descending aorta are shown in blue. D, Quantitative analysis of 
atherosclerotic plaque volume in the IC of the aortic arch, the proximal IA, LCCA, and 
LSCA, the sum of branches (IA + LCCA + LSCA) or the total aorta (sum of branches + 
IC of aortic arch) of pecam-1+/+ldlr−/− (filled bars; n=6) vs pecam-1−/−ldlr−/− (open 
bars; n=5) mice maintained on a HFD for 24 weeks. Results are expressed as mean 
plaque volume ±SE. Asterisks denote statistically significant differences between 
groups (*P<0.05, ***P<0.001). 
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Endothelial Cell PECAM-1 Expression Protects Against 
Development of Atherosclerosis in the Aortic Sinuses of 
LDLR-Deficient Mice 
PECAM-1 is expressed on both endothelial cells and bone 
marrow–derived leukocytes and platelets, and is capable of 
transducing signals that affect the function of cells from both of these 
compartments.30 It was therefore important to determine whether the 
effects of PECAM-1 on atherosclerosis required its expression on 
endothelial cells, bone marrow–derived cells, or both. We created bone 
marrow chimeric ldlr−/− mice that selectively expressed PECAM-1 either 
on endothelium or bone marrow–derived cells (supplemental Figure I), 
and measured atherosclerotic lesion sizes after feeding these mice a 
HFD for 24 weeks. Unfortunately, the bone marrow transplantation 
experiments did not recapitulate decreased lesion formation in the 
lesser curvature of the arch in pecam-1−/− mice. The lesion area along 
the inner curvature of the arch of ldlr−/− mice was comparable in 
pecam-1+/+ recipients of pecam-1+/+ marrow and pecam-1−/− 
recipients of pecam-1−/− marrow (supplemental Figure IV); therefore, 
we could not use bone marrow chimeric mice to determine whether 
endothelial or bone marrow–derived leukocyte or platelet expression of 
PECAM-1 enhances lesion development in this region. However, like 
untransplanted pecam-1−/−ldlr−/− relative to pecam-1+/+ldlr−/− mice, 
pecam-1−/− recipients of pecam-1−/− bone marrow developed larger 
lesions in the aortic sinus (Figure 4A) and total aorta (Figure 4B) 
relative to pecam-1+/+ recipients of pecam-1+/+ marrow. Thus, bone 
marrow chimeric mice could be used to determine the effects of 
endothelial versus hematopoietic cell expression of PECAM-1 on lesion 
development in the aortic sinus and total aorta of ldlr−/− mice.  
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Figure 4. The effect of endothelial cell vs blood cell PECAM-1 expression on 
development of atherosclerosis in LDLR–deficient mice. A, Endothelial cell PECAM-1 
protects against development of atherosclerosis in the aortic sinus. Each symbol 
represents the mean percent atherosclerotic lesion area calculated from 4 to 6 oil red 
O–stained sections spanning the aortic sinus of an individual pecam-1+/+ldlr−/− (filled 
symbols) or pecam-1−/−ldlr−/− (open symbols) recipient mouse transplanted with 
pecam-1+/+ldlr−/− (squares) or pecam-1−/− ldlr−/− (circles) donor bone marrow and 
maintained on a HFD for 24 weeks. Horizontal lines indicate the mean percent aortic 
sinus lesion area for each group of animals. Asterisks denote statistically significant 
differences between groups (*P<0.05, **P<0.01). B, Endothelial cell and blood cell 
PECAM-1 expression are required for PECAM-1–mediated protection against 
development of atherosclerosis in the aorta. Each symbol represents the percent of 
total area of the indicated section of aorta that stained positively for oil red O in an 
individual pecam-1+/+ ldlr−/− (filled symbols) or pecam-1−/−ldlr−/− (open symbols) 
recipient mouse transplanted with either pecam-1+/+ldlr−/− (squares) or pecam-
1−/−ldlr−/− (circles) donor bone marrow and maintained on a HFD for 24 weeks. 
Horizontal lines indicate mean percent lesion area in the indicated aortic section, 
including the thoracic aorta, abdominal aorta, and total aorta (aortic arch + thoracic 
aorta + abdominal aorta), for each group of animals. Asterisks denote statistically 
significant differences between groups (*P<0.05, **P<0.01). 
In the aortic sinus, lesions that developed in pecam-1+/+ 
recipients of pecam-1−/− marrow were similar in size to those of 
pecam-1+/+ recipients of pecam-1+/+ marrow, and significantly smaller 
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than the lesions that developed in pecam-1−/− recipients of pecam-1−/− 
marrow (Figure 4A). Also, lesions that developed in the aortic sinuses 
of pecam-1−/− recipients of pecam-1+/+ marrow were similar in size to 
those of pecam-1−/− recipients of pecam-1−/− marrow and significantly 
larger than the lesions that developed in pecam-1+/+ recipients of 
pecam-1+/+ marrow (Figure 4A). These results indicate that endothelial 
cell expression of PECAM-1 inhibits development of atherosclerotic 
lesions in the aortic sinuses of ldlr−/− mice. 
Interestingly, mice that were missing PECAM-1 from either 
endothelial cells, bone marrow–derived leukocytes or platelets, or both 
exhibited a trend toward increased lesion sizes in the thoracic and 
abdominal aorta relative to mice that expressed PECAM-1 on both 
endothelial and bone marrow–derived cells; however, these differences 
did not reach statistical significance until lesion areas in the total aorta 
were compared (Figure 4B). These results indicate that expression of 
PECAM-1 on both endothelial and bone marrow–derived leukocytes or 
platelets is required for PECAM-1 to inhibit development of 
atherosclerotic lesions in the aortas of ldlr−/− mice. 
Discussion 
The major finding of this study is that PECAM-1 expression 
affects development of atherosclerosis differently at different lesion-
prone sites of the vasculature. Specifically, PECAM-1 is 
proatherosclerotic in the inner curvature of the aortic arch, but 
atheroprotective in the aortic sinus, branching arteries, and 
descending aorta. The atheroprotective effect of PECAM-1 in the aortic 
sinus requires PECAM-1 expression only on endothelial cells, whereas 
PECAM-1 expression on both endothelial cells and bone marrow–
derived cells is required for its atheroprotective effects in the 
descending aorta. 
The proatherosclerotic effect of PECAM-1 in the inner curvature 
of the arch is consistent with its role as part of a mechanostimulatory 
complex on endothelial cells that activates NF-kB in response to low 
shear stress and induces expression of adhesion molecules that enable 
recruitment of inflammatory cells into the lesion.9 A 
mechanostimulatory function for PECAM-1 is supported by the findings 
in many,9,31–33 but not all,34 studies that PECAM-1 facilitates responses 
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of cultured endothelial cells to osmotic and fluid shear stresses. 
Previous studies have established that PECAM-1 is rapidly 
phosphorylated on cytoplasmic tyrosine residues in cultured 
endothelial cells exposed to fluid shear or osmotic stress31–36; however, 
whether PECAM-1 tyrosine phosphorylation is required for its 
mechanostimulatory function is not yet known. 
The atheroprotective effect of PECAM-1 in the aortic sinus, 
branching arteries, and descending aorta indicates that PECAM-1 
normally inhibits development of atherosclerosis in these regions of 
the vasculature. Our studies of bone marrow chimeric mice revealed 
that the cells on which PECAM-1 must be expressed to inhibit lesion 
development vary by vascular region. Specifically, in both the aortic 
sinus and descending aorta, the atheroprotective effect of PECAM-1 
required its expression on endothelial cells; in the aortic sinus, PECAM-
1 expression on endothelial cells alone was sufficient for its inhibitory 
function. Two functions of the endothelium that impact lesion 
development in atherosusceptible regions include maintenance of the 
vascular permeability barrier and insurance of nitric oxide (NO) 
bioavailability.2 PECAM-1 has been shown to support maintenance of 
vascular integrity in at least 4 different models of inflammation, 
including intradermal injection of histamine,11 autoimmune 
encephalomyelitis,11 collagen-induced arthritis,12,15 and 
lipopolysaccharide (LPS)-induced endotoxemia.13,14 PECAM-1 deficiency 
has also been shown to affect NO bioavailability, either as a 
consequence of decreased production of NO19 or increased production 
of reactive oxygen species.20 Thus, either increased vascular 
permeability or decreased NO bioavailability could contribute to the 
increased atherosclerosis observed in the aortic sinuses and 
descending aortas of mice with PECAM-1–deficient relative to PECAM-
1–positive endothelium. 
The inhibitory effect of PECAM-1 on lesion development in the 
aorta as a whole, in contrast, required its expression not only on 
endothelial cells but also on hematopoietic cells. The hematopoietic 
cells thought to play crucial roles in atherosclerotic lesion development 
include monocytes, T lymphocytes, and platelets.1,3 There is ample 
evidence that PECAM-1 inhibits platelet responsiveness,30,37 and 
PECAM-1 is also capable of interfering with both macrophage-mediated 
phagocytosis of viable cells38,39,40 and T cell receptor–mediated 
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signaling pathways.41 Indeed, loss of PECAM-1 from circulating T cells 
correlated with occurrence of atherothrombotic plaque complications in 
humans42 and mice.43 Furthermore, in vivo administration of PECAM-
1/IgG fusion proteins reduced lesion sizes in atherosusceptible mice 
coincident with blunted T cell activation, increased numbers of 
circulating regulatory T cells, and decreased infiltration of T cells into 
accumulating plaque.44 Collectively, these studies support the 
conclusion that interactions between PECAM-1–expressing endothelial 
cells and either platelets, monocytes, or T cells may decrease 
atherosclerosis in aortas of PECAM-1–positive relative to PECAM-1–
negative mice. Studies in which the pecam-1 gene is knocked out in 
specific types of hematopoietic cells are needed to determine the 
extent to which PECAM-1 expression by any one of these cell types 
normally interferes with development of atherosclerosis. 
Finally, our findings indicate that PECAM-1 has both 
proatherosclerotic and atheroprotective effects on the vasculature; 
however, each of these opposing effects dominates in a different 
region of the vasculature. Thus, the inner curvature of the arch is 
more strongly influenced by the mechanostimulatory and therefore 
proatherosclerotic function of PECAM-1, whereas other 
atherosusceptible regions of the vasculature are more strongly 
influenced by its antiinflammatory and therefore atheroprotective 
effects. A possible explanation for the differential sensitivity of these 
regions to the mechanosensory versus antiinflammatory roles of 
PECAM-1 is that PECAM-1 might influence the type or magnitude of 
hemodynamic shear stress to which different regions of the 
vasculature are exposed, which can be addressed by comparing the 
hemodynamic properties of PECAM-1+/+ versus PECAM-1−/− aortas.45 
Alternatively, PECAM-1 might contribute in different ways to the 
responses of cells in different regions of the vasculature, even if they 
are exposed to the same shear stresses. This possibility is consistent 
with the concept that site-specific responses to systemic factors 
modulate how atherosclerosis develops in different atherosusceptible 
regions.2 In either case, by demonstrating that PECAM-1 both 
promotes and impedes development of atherosclerotic lesions in site-
specific ways, our findings provide a more complete understanding of 
the factors that interact in complex ways to control initiation and 
progression of atherosclerosis. 
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